AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-24. (Canceled)

Claim 25. (Currently Amended) A method for treating a wound and/or improving wound healing wherein a therapeutically effective amount of a pharmaceutical composition comprising a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.

Claim 26. (Original) A method according to claim 25, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.

Claim 27. (Currently Amended) A method according to claim 25 ~~or 26~~, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF and IL-1.

Claim 28. (Currently Amended) A method according to ~~any one of the claims 25—27~~ claim 25, for treatment of posttraumatic tissue injury.

Claim 29. (Original) A method according to claim 28, wherein said posttraumatic tissue injury is caused by surgery.

Claim 30. (Currently Amended) A method according to ~~any one of the claims 25—27~~ claim 25, for treatment of thermic injury.

Claim 31. (Currently Amended) A method according to ~~any one of the claims 25—27~~ claim 25, for treatment of a wound resulting from a metabolic process due to reduced nutritional supply.

Claim 32. (Original) A method according to claim 31, for treatment of a diabetic ulcer, a leg ulcer, a decubitus ulcer or a gastric ulcer.

Claim 33. (Currently Amended) A method according to ~~any one of the claims 25—27~~ claim 25, for treatment of a wound resulting from exposure to a toxic compound.

Claim 34. (Currently Amended) A method according to ~~any one of the claims 25—33~~ claim 25, wherein said substance is a monoclonal antibody.

Claim 35. (Original) A method according to claim 34, wherein said substance is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870.

Claim 36. (Currently Amended) A method according to ~~any one of the claims 25 — 33~~ claim 25, wherein said substance is a soluble cytokine receptor.

Claim 37. (Original) A method according to claim 36, wherein said substance is etanercept.

Claim 38. (Currently Amended) A method according to ~~any one of the claims 25 — 33~~ claim 25, wherein said substance is a receptor antagonist.

Claim 39. (Currently Amended) A method according to ~~any one of the claims 25 — 33~~ claim 25, wherein said substance is an antisense oligonucleotide.

Claim 40. (Currently Amended) A method according to ~~any one of the claims 25 — 33~~ claim 25, wherein said substance is an MMP inhibitor selected from the group consisting of tetracyclines, chemically modified tetracyclines, Prinomastat, Batimastat, Marimastat, KB-R7785, TIMP-1, TIMP-2, adTIMP-1, and adTIMP-2.

Claim 41. (Currently Amended) A method according to ~~any one of the claims 25 — 33~~ claim 25, wherein said substance is an quinolones selected from the group consisting of Norfloxacin, Levofloxacin, Enoxacin, Sparfloxacin, Temafloxacin, Moxifioxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Trovafloxacin, Ofloxacin, Ciprofloxacin, Pefloxacin, Lomefloxacin, and Temafloxacin.

Claim 42. (Currently Amended) A method according to ~~any one of the claims 25—33~~ claim 25, wherein said substance is a thalidomide derivate selected from the group consisting of CC-1088, CDC-501, CDC-801 and Linomide.

Claim 43. (Currently Amended) A method according to ~~any one of the claims 25—33~~ claim 25, wherein said substance is selected from the group consisting of prostaglandins, phosphodiesterase I, II, III, IV, and V-inhibitors, cyclosporin, pentoxifyllin derivates, hydroxamic acid derivates, melanin and melancortin agonists, and lazaroids.

Claim 44. (Currently Amended) A method according to ~~any one of the claims 25—33~~ claim 25, wherein said substance is a specific IL-1α and/or IL-1β blocking substance.

Claim 45. (Currently Amended) A method according to ~~any one of the claims 25—33~~ claim 25, wherein said substance is a non-specific IL-1α and/or IL-1β blocking substance.

Claim 46. (Currently Amended) A method according to ~~any one of the claims 25—33~~ claim 25, wherein said substance is lactoferrin or a peptide derived or derivable from lactoferrin.

Claim 47. (Currently Amended) A method according to ~~any one of the claims 25—46~~ claim 25, wherein said substance is locally administered.

Claim 48. (Currently Amended) A method according to ~~any one of the claims 25 — 46~~ claim 25, wherein said substance is systemically administered.